Skip to content

Psychedelic-assisted therapy: all studies

Page 174 of 294: studies 1,731 to 1,740 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

Epigenetic Echoes: Bridging Nature, Nurture, and Healing Across Generations.

International Journal of Molecular Sciences March 27, 2025 Blerida Banushi, Jemma Collova, Helen Milroy 19 citations

Trauma can impact individuals within a generation (intragenerational) and future generations (transgenerational) through a complex interplay of biological and environmental factors. This review explores the epigenetic mechanisms that have been correlated with the effects of trauma across generations, including DNA methylation, histone modifications, and non-coding RNAs. These mechanisms can...

A UHPLC-(ESI)MS/MS method for the determination of the psychedelic secondary metabolite mescaline in San Pedro (Trichocereus spp.) and its applicability for screening mescaline in other cacti varieties.

Forensic Chemistry March 25, 2025 Pragna Gaur, Liam Engel, Damian Robert Hall et al. 1 citation

Commencements of clinical trials of psychedelic therapies for intractable forms of mental illnesses have drawn increased public attention to plants containing psychedelic substances. Whilst the psychoactive alkaloid mescaline has limited clinical trials, the San Pedro ( Trichocereus spp.) cacti from which it is found have a long history of Indigenous medical and spiritual use. Traditional use...

DOI: 10.1016/j.forc.2025.100659 (opens in new tab) Mescaline Secondary metabolite Chromatography Traditional medicine +2

Mixed-Methods Study of Use and Attitudes About Psychedelics for Therapeutic Purposes Among Low-Income U.S. Veterans Nationally.

Journal of Psychoactive Drugs March 24, 2025 Jack Tsai, Laura Witte, Taylor Fate

There is great public and clinical interest in the use of psychedelics for therapeutic purposes. However, there has been little national study of psychedelic use in the U.S. veteran population. This study used quantitative and qualitative data from a nationally representative survey of 1,031 low-income U.S. veterans who participated in the National Veteran Homeless and Other Poverty Experiences...

Structural basis for psilocybin biosynthesis.

Nature Communications March 22, 2025 Chunyan Meng, Wenting Guo, Chuan Xiao et al. 4 citations

Psilocybin shows significant therapeutic potential for psilocybin-assisted psychotherapy in addressing various psychiatric conditions. The biosynthetic approach promises rapid and efficient production of psilocybin. Understanding the enzymes that contribute to the biosynthesis of psilocybin can enhance its production process. In this study, we elucidate the crystal structures of...

DOI: 10.1038/s41467-025-58239-x (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Biochemistry Pharmaceutical research +1

Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review.

Medicina (Kaunas, Lithuania) March 21, 2025 Keming Gao, Evrim Bayrak Oruc, Buket Koparal 9 citations

Objective: To narratively review currently available antidepressants and future potential antidepressants as monotherapy for the treatment of depressive disorders. Methods: Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake inhibitor (bupropion), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) were...

DOI: 10.3390/medicina61040558 (opens in new tab) Full text (opens in new tab) N-methyl-d-aspartate receptor antagonists Anti-inflammatory agents Biomarker antidepressant therapy Depressive disorders +9

Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025 Zhen Xuen Brandon Low, Shin Jie Yong, Hayam A Alrasheed et al.

In our ongoing battle against the coronavirus 2019 (COVID-19) pandemic, a major challenge is the enduring symptoms that continue after acute infection. Also known as Long COVID, post-COVID-19 syndrome (PCS) often comes with debilitating symptoms like fatigue, disordered sleep, olfactory dysfunction, and cognitive issues ("brain fog"). Currently, there are no approved treatments for PCS. Recent...

Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?

Dialogues in Clinical Neuroscience March 19, 2025 Michael Davidson, Gabriela-Dumitrita Stanciu, Jonathan Rabinowitz et al. 2 citations

The increasing prevalence of dementia within an ageing global population, combined with prolonged life expectancy, accentuates Alzheimer's disease (AD) as a multifaceted healthcare challenge. This challenge is further compounded by the limited therapeutic options currently available. Addressing the intricacies of AD management, the mitigation of comorbidities has emerged as a pivotal facet of...

DOI: 10.1080/19585969.2025.2480566 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Alzheimer's disease Brain research

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial

Frontiers in Pain Research March 18, 2025 Jenna McAfee, Avinash Hosanagar, Vijay Tarnal et al. 18 citations

Introduction Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Currently, there are limited treatment options available that effectively treat FM symptoms. Psilocybin-assisted therapy (PAT) is an emerging combined drug-therapy intervention, but no studies to-date have investigated PAT for FM. Methods...

DOI: 10.3389/fpain.2025.1527783 (opens in new tab) Psilocybin Clinical trial Fibromyalgia Open label +2

Psychedelics and autobiographical memory - six open questions.

Psychopharmacology March 17, 2025 Samuli Kangaslampi, Morten P. Lietz 10 citations

Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memories has further been suggested to be a major component of the therapeutic action of psychedelics. However, modern psychedelic research has largely neglected autobiographical elements of psychedelic experiences, and many vital questions remain...

The renaissance of psychedelics in modern psychiatry: a new breakthrough or the myth of a “magic bullet”?

Neurology Bulletin March 15, 2025 V. Skryabin

In recent years, there has been a significant surge of interest in psychedelic research. These studies encompass both neuroscience and their potential clinical applications. This phenomenon, often referred to as the "Psychedelic Renaissance", includes studies on compounds such as psilocybin, MDMA, DMT, and LSD used for the treatment of depression, post-traumatic stress disorder, anxiety, and...